PURPOSE: To observe which symptoms of transthyretin-related familial amyloidotic polyneuropathy (FAP) progressed in the long term after liver transplantation (LT), focusing on cardiac, kidney, and ocular symptoms. METHODS: We reviewed the medical records of 34 Japanese patients with FAP, who underwent LT between 1994 and 2006. The mean follow-up period (± SD) after LT was 9.6 ± 3.4 years. Of the 34 patients, 30 had FAP amyloidogenic transthyretin (ATTR) Val30Met, 1 had FAP ATTR Ser50Ile, and 3 had FAP ATTR Tyr114Cys. RESULTS: The 10-year survival rates from the onset of FAP and from the time of LT were 100% and 91.4%, respectively. Progression of ocular amyloidosis was seen in 17 (50%) patients, 13 of whom had de novo amyloid deposits in the vitreous body; progression of cardiac amyloidosis was seen in 10 (29%) patients, 4 of whom had newly granular sparkling echo on echocardiography, and 9 of whom had newly implanted pacemakers or implantable cardioverter-defibrillators. Although the mean serum creatinine levels did not increase significantly after LT in any of the patients, the estimated glomerular filtration rate had decreased significantly by 7 years after LT. CONCLUSION: Although LT is life-saving for patients with FAP, we observed progression of the ocular and cardiac symptoms of FAP in a significant number of these patients over the long term after LT.
PURPOSE: To observe which symptoms of transthyretin-related familial amyloidotic polyneuropathy (FAP) progressed in the long term after liver transplantation (LT), focusing on cardiac, kidney, and ocular symptoms. METHODS: We reviewed the medical records of 34 Japanese patients with FAP, who underwent LT between 1994 and 2006. The mean follow-up period (± SD) after LT was 9.6 ± 3.4 years. Of the 34 patients, 30 had FAP amyloidogenic transthyretin (ATTR) Val30Met, 1 had FAPATTR Ser50Ile, and 3 had FAPATTR Tyr114Cys. RESULTS: The 10-year survival rates from the onset of FAP and from the time of LT were 100% and 91.4%, respectively. Progression of ocular amyloidosis was seen in 17 (50%) patients, 13 of whom had de novo amyloid deposits in the vitreous body; progression of cardiac amyloidosis was seen in 10 (29%) patients, 4 of whom had newly granular sparkling echo on echocardiography, and 9 of whom had newly implanted pacemakers or implantable cardioverter-defibrillators. Although the mean serum creatinine levels did not increase significantly after LT in any of the patients, the estimated glomerular filtration rate had decreased significantly by 7 years after LT. CONCLUSION: Although LT is life-saving for patients with FAP, we observed progression of the ocular and cardiac symptoms of FAP in a significant number of these patients over the long term after LT.
Authors: M Yazaki; S Mitsuhashi; T Tokuda; F Kametani; Y-I Takei; J Koyama; A Kawamorita; H Kanno; S-I Ikeda Journal: Am J Transplant Date: 2006-10-25 Impact factor: 8.086
Authors: Volker Schmitz; Sven Laudi; Franziska Moeckel; Gero Puhl; Martin Stockmann; Zung Vu Tran; Andreas Kahl; Ulf Neumann; Peter Neuhaus Journal: Clin Transplant Date: 2008-03-12 Impact factor: 2.863
Authors: Renaud Snanoudj; Antoine Durrbach; Eric Gauthier; David Adams; Didier Samuel; Sophie Ferlicot; Pierre Bedossa; Alain Prigent; Henri Bismuth; Bernard Charpentier Journal: Nephrol Dial Transplant Date: 2004-05-18 Impact factor: 5.992
Authors: Y Ando; Y Tanaka; M Nakazato; B G Ericzon; T Yamashita; K Tashima; N Sakashita; M Suga; M Uchino; M Ando Journal: Biochem Biophys Res Commun Date: 1995-06-15 Impact factor: 3.575
Authors: Stephen Connelly; David E Mortenson; Sungwook Choi; Ian A Wilson; Evan T Powers; Jeffery W Kelly; Steven M Johnson Journal: Bioorg Med Chem Lett Date: 2017-05-26 Impact factor: 2.823
Authors: Alejandra González-Duarte; Isabel Conceição; Leslie Amass; Marc F Botteman; John A Carter; Michelle Stewart Journal: Neurol Ther Date: 2020-03-31